Schwarz Pharma Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Mequon WI United States (1985)
Status: Acquired by UCB (2006)

Organization Overview

First Clinical Trial
2002
NCT01761526
First Marketed Drug
1985
prednisone (meticorten)
First NDA Approval
2007
rotigotine (neupro)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sanol GmbH | Schwarz BioSciences GmbH | SCHWARZ PHARMA

Active Ingredients

Marketed Drugs (5)

acetylsalicylic acid (aspirin) (1988)

fesoterodine (toviaz) (1998)

hydrocodone (hycodan) (1988)

prednisone (meticorten) (1975)

rotigotine (neupro) (2007 NDA)

Drugs in Phase 3 Trials (2)

ferrous glycine sulphate complex (1 trial)

polyferose (1 trial)

Drugs in Phase 2 Trials (2)

Key: Schwarz Pharma (1) Acquired (1)

rotigotine (neupro) (2 trials)

selodenoson (1 trial)

Indications

Approved Indications


 

Depression

Parkinson Disease

Restless Legs Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Deficiency Diseases (Phase 3)

Psychomotor Agitation (Phase 2)

Restless Legs Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4